Core Viewpoint - Via Biotechnology (01873) experienced a nearly 7% intraday increase, closing up 4.21% at HKD 1.98, with a trading volume of HKD 16.048 million [1] Group 1: Company Developments - Via Biotechnology hosted an innovation seminar during the 44th J.P. Morgan Healthcare Conference on January 13, focusing on advancements in artificial intelligence and new drug types [1] - The seminar highlighted the role of AI in the entire process of peptide drug development and the AI-enabled peptide CRDMO platform, showcasing how AI is accelerating implementation in key research and industrialization stages [1] Group 2: Business Performance - Huaxin Securities reported that Via Biotechnology's CRO business primarily serves early drug discovery, representing a significant application of AI that enhances drug development efficiency and success rates [1] - The company launched an AI-integrated drug development platform called AIDD, which has participated in the development of 175 projects by mid-2025, with AI-enabled CRO business accounting for 10% of total revenue [1]
港股异动 | 维亚生物(01873)盘中涨近7% 维亚生物创新研讨会呈现生物医药研发新路径